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Genome-wide burden of deleterious coding
variants increased in schizophrenia
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Schizophrenia is a common complex disorder with polygenic inheritance. Here we show
that by using an approach that compares the individual loads of rare variants in
1,042 schizophrenia cases and 961 controls, schizophrenia cases carry an increased burden of
deleterious mutations. At a genome-wide level, our results implicate non-synonymous, splice
site as well as stop-altering single-nucleotide variations occurring at minor allele frequency of
Z0.01% in the population. In an independent replication sample of 5,585 schizophrenia
cases and 8,103 controls of European ancestry we confirm an enrichment in cases of the
alleles identified in our study. In addition, the genes implicated by the increased burden of
rare coding variants highlight the involvement of neurodevelopment in the aetiology of
schizophrenia.
DOI: 10.1038/ncomms8501 OPEN
1 Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, California 90095, USA. 2Department of Psychiatry, Brain Center
Rudolf Magnus, University Medical Center Utrecht, Utrecht 3584 CG, The Netherlands. 3MRC Centre for Psychiatric Genetics and Genomics, Cardiff
University, Cardiff CF24 4HQ, UK. 4Department of Human Genetics, University of California Los Angeles, Los Angeles 90095, USA. wA full list of consortium
members appears at the end of the paper. Correspondence and requests for materials should be addressed to R.A.O. (email: ophoff@ucla.edu).
NATURE COMMUNICATIONS | 6:7501 | DOI: 10.1038/ncomms8501 | www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
D
espite the high heritability of schizophrenia, identifying
the contributing genetic variants has been a daunting
challenge. In addition to common variants that continue
to be revealed by conventional genome-wide association studies
(GWAS)1, rare variants, including de novo mutations2,3 and
genomic copy-number variants4,5, have been found to play a role
in disease risk. However, due to their low minor allele frequencies
(MAFs) and modest effect sizes, it is difficult to establish
associations with rare SNVs using standard association tests. For
this reason, we investigated the burden of rare SNVs in
schizophrenia by an individual set-unique burden (ISUB)
analysis of coding variants that occur in cases or controls, but
not both. While our method does not rely on frequency
thresholds, in practice, ISUB includes variants with MAFs
ranging from 0.05 to 0.6% in our study, and with a mean of
0.05% in the population. A previous finding suggests enrichment
of primarily singleton nonsense variants in schizophrenia in a set
of pre-selected genes6. In contrast, we examine a genome-wide
distribution not limited to a subset of genes previously associated
with the disease. In addition, instead of studying extremely rare
loss-of-function variants we include rare but recurrent variants in
the population (MAF41:10,000) with milder deleteriousness
criteria. Because of this approach, we are able to study the
individual cumulative burden rather than burden across groups of
cases and controls. To quantify the individual burden of variants
in our sample, we incorporated scores from a previously
developed CONsensus DELeteriousness (CONDEL) algorithm7
aimed at assessing the impact of non-synonymous SNVs on
protein function.
Our results show an increased burden of rare deleterious
coding variants in cases versus controls. Our findings implicate
non-synonymous as well as stop-altering and splice site SNVs at a
genome-wide level. Functional enrichment analysis of genes
impacted by rare variant burden highlights the involvement of
neurodevelopment in the aetiology of schizophrenia. Finally, we
observe no clear link between common and rare susceptibility
alleles and their relative contribution to the disease. Our results
underscore the polygenic nature of schizophrenia across the
allelic spectrum.
Results
Sample description and variant selection. We collected coding
sequence variation in 1,042 schizophrenia patients and 961
controls using the Illumina HumanExome BeadChip array. From
a total of 100,857 variants observed in our sample, 75,837 are
protein-coding SNVs that were scored by ISUB. From these,
16,262 occurred only in cases, of which 6,424 are predicted to
be deleterious. For controls, 12,964 were set-unique non-
synonymous, with a total of 5,130 predicted to be deleterious (see
Fig. 1). The number of observations ranges from 1 to 12 per SNV
with a mean of 1.43 (median¼ 1) in cases and a mean of 1.39
(median¼ 1) in controls. The mean MAF of the set-unique
variants included in our study is 0.05% in the population based
on individuals of European Ancestry included in ESP6500.
Increased burden of rare variants in schizophrenia. The
genome-wide ISUB for deleterious variants is increased
significantly in cases versus controls (empirical P¼ 0.018) (see
Table 1, Supplementary Fig. 1 and Supplementary Table 1).
Although a similar difference is observed for the set of all non-
synonymous variants (NS, empirical P¼ 0.033), the signal is
driven primarily by deleterious variants (DEL, empirical
P¼ 0.018) and not by the complementary set of non-synonymous
variants predicted to be non-deleterious (NS—DEL, empirical
P¼ 0.492), as indicated by the information in Table 1 (Methods).
Given the differences in rare variants between cases and controls,
we investigate the nature, robustness and polygenicity of this
observed increase. To illustrate, the increased burden may be
caused by a larger number of variants per individual or by an
increased predicted deleteriousness per SNV, or both. To this end,
we characterized the quantitative/qualitative nature of the
observed increase. Although not completely independent, our
results suggest that the increased individual burden is primarily
due to a larger number of rare deleterious SNVs (empirical
P¼ 0.015), rather than the SNVs in patients being more
deleterious (empirical P¼ 0.079, Supplementary Table 1).
In an independent replication sample of 5,585 schizophrenia
cases and 8,103 controls of European ancestry we observe an
increased frequency of the deleterious variants identified through
ISUB: cases have an average of 3.4 of the total of 6,424 deleterious
variants observed only in cases, compared with 3.3 in controls
(empirical P¼ 0.035).
These results are unlikely to represent an artefact caused by
population stratification or cryptic relatedness for several reasons:
(1) we performed stringent quality control (Supplementary
Methods, and Supplementary Fig. 2); (2) ISUB score is a
significant predictor of case–control status, even after including
the first ten MDS components into the model (Supplementary
Methods); and (3), we observe the same increased frequency in
two independent samples of European Ancestry.
Polygenic nature of the increased burden. To assess the
polygenicity of the observed increase in burden as well as identify
the contributions of the different types of variants, we next
analysed the number of genes affected by the different types of
variants. The variants we tested are (a) all deleterious variants,
(b) splice site variants, (c) stop-altering variants and (d) so-called
‘double hits’. The latter includes genes with two or more non-
synonymous SNVs within one individual, where we require at
least one to be predicted to be deleterious. As summarized in
Table 2, a greater number of genes are affected by deleterious rare
variants in cases versus controls (4,533 genes in cases versus 3,795
in controls, empirical P¼ 0.008, Table 2). More striking is that in
cases an increased number of genes is affected by splice site
variants (380 genes in cases versus 276 in controls, empirical
P¼ 0.016) as well as stop-altering stop-altering variants (350 and
253 genes respectively empirical P¼ 0.004). We observe a trend
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Figure 1 | Set-unique SNVs. Diagram depicting the set-unique variants
(not to scale, cases n¼ 1,002, controls n¼931). The set NS represents all
variants that are scored by ISUB, and the set DEL includes only those
variants that are predicted to be deleterious. In particular, the set DEL
includes stop-altering and splice site variants.
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in the number of genes with two or more non-synonymous SNVs
(179 genes in cases, 103 in controls, empirical P¼ 0.047), but this
difference does not survive correction for multiple testing.
To further investigate the polygenicity of rare variant burden, we
excluded the variants in a set of genes shown in previous work
to be most prominently enriched for rare disruptive mutations
in schizophrenia (n¼ 1,796)6. In this analysis, the observed
difference in deleterious ISUB remains significant (empirical
P¼ 0.006) (Supplementary Methods).
Functional classification of rare deleterious variants. To classify
the genes implicated by ISUB analysis at a functional level, we
examined tissue expression enrichment and pathway analysis
using DAVID (database for annotation, visualization and
integrated discovery)8. To restrict the total set of genes to a
number suitable for DAVID analysis (no3,000), we selected the
genes with increased load of rare variants based on Fisher exact
P-values (see Methods and Supplementary Methods for the
precise definition of these genes with strongest evidence). This
approach not only reduces the set of genes to a usable size
(from 4,533 to 698 in cases), it also reduces noise from highly
polymorphic genes with large number of non-synonymous
variants seen in both cases and controls (for example, NEB in
which 12 controls and 9 cases have at least one deleterious SNV,
and MUC16 with 6 controls and 12 cases9). Interestingly, we
observed significant enrichment for genes expressed in fetal brain
(uncorrected P¼ 0.001, Benjamini corrected P¼ 0.033, hyper-
geometric overlap test). To control for potential confounders such
as gene length, we performed the same analysis in controls, and
while some enrichments were observed, fetal brain genes were not
significantly enriched (Supplementary Table 2). Pathway analysis
points to the extracellular matrix (ECM) receptor interaction as
the only significantly enriched pathway in cases (P¼ 5.87E 05,
Benjamini corrected P¼ 8.30E 03, hypergeometric overlap
test), whereas no pathway enrichment was observed in controls.
The above results were confirmed by a permutation analysis
sampling an equal number of cases and controls (931 individuals
for both groups, Supplementary Table 3, Supplementary
Methods).
Relationship between common and rare susceptibility alleles.
Given the increased individual burden of rare coding variants in
schizophrenia, we next examined the relationship between com-
mon and rare susceptibility alleles. We tested the overlap between
genes located in schizophrenia associated intervals from the
GWAS study of the Psychiatric Genomics Consortium1 (ED
Supplementary Table 3) and the genes implicated in our study.
No significant overlap was observed in cases (83 overlap the 4,533
genes with deleterious alleles in cases versus 62/3,795 in controls,
empirical P¼ 0.070, Supplementary Table 2, Supplementary
Methods). We also did not observe a correlation between ISUB
score and sex (Supplementary Methods).
Quantifying the contribution of these variants to disease
susceptibility, by odds ratios and similar statistics, is not suitable
for low frequency alleles. For this reason, we measured the
relative effect size by reduction in Nagelkerke’s R2 from logistic
regression, and compared it with the relative impact of common
SNVs using polygenic risk scores of the most recent GWAS
results1. These regressions showed relative effect sizes of 10.7%
for GWAS common alleles compared with 0.6% for rare
deleterious alleles identified through ISUB (Supplementary
Methods). Thus, common alleles contribute an order-of-
magnitude more to disease susceptibility than the rare
deleterious variants, in line with evidence presented by Purcell,
et al.6. When comparing the polygenic risk score of cases with
ISUB scores directly, no correlation was observed (Supplementary
Methods). This suggests that common and rare disease risk alleles
may be independently and additively enriched in cases versus
controls.
Finally, we tested the overlap between our gene sets and the set
of genes containing previously reported de novo mutations in
schizophrenia2,3,10,11. While the difference between cases and
controls is not significant (empirical P¼ 0.070), we observe a
highly significant overlap within each group (Po2.2e 16 for
cases and P¼ 4.44e 16 for controls, Supplementary Methods,
hypergeometric overlap test).
Discussion
Our results demonstrate the contribution of non-synonymous
rare variants to the aetiology of schizophrenia. In the same
frequency spectrum of previously observed rare variants, we
identify not only a significant genome-wide increased individual
burden of deleterious non-synonymous variants, but also an
increased burden of stop-altering and splice site variants.
Table 1 | Individual set-unique burden (ISUB) analysis.
Variant type Disease Status Number of SNVs Individual burden score (mean/median/s.d.) P value
NS Case 16,262 8.73/ 7.26/ 9.65
0.033
Control 12,964 7.27/ 6.56/ 5.62
DEL Case 6,424 7.54/ 6.29/ 8.18
0.018
Control 5,130 6.23/ 5.58/ 4.78
NS—DEL Case 9,838 1.18/ 0.94/ 1.62
0.492
Control 7,834 1.04/ 0.85/ 1.07
The number of set-unique SNVs and mean individual burden score for all non-synonymous variants (NS) as well as the two complementary subsets of only deleterious (DEL) variants as well as non-
synonymous variants not predicted to be deleterious (NS-DEL). Empirical P-values are estimated by permutation (10,000 permutations) of the phenotypes (cases n¼ 1,002, controls n¼ 931) based on
Wilcoxon Rank Sum Test statistics. See also Supplementary Fig. 1 and Supplementary Table 1. Values in bold withstands correction for multiple testing (Supplementary Methods).
Table 2 | Set-unique burden of different variant types.
Variant Type Disease status Total genes P value
Deleterious genes Case 4,533
0.008
Control 3,795
Splice site Case 380
0.016
Control 276
Stop-altering Case 350
0.004
Control 253
Double hits Case 179
0.047
Control 103
The polygenic burden of deleterious hits, splice site and stop-altering variants and double hits
arising from set-unique SNVs (cases n¼ 1,002, controls n¼ 931). The category of double hits
includes those genes for which an individual has two or more SNVs (of which at least one is
predicted to be deleterious) within the borders of the gene. Each row contains the number of
genes having at least one variant. Empirical P values for the difference in gene count are
estimated empirically by permutation of phenotypes. Values in bold withstand correction for
multiple testing (Supplementary Methods).
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The deleterious variants identified through our analysis also
occur at an increased frequency in cases compared with controls
in an independent replication sample. Thus, not only does the
increased burden of rare variants contribute to schizophrenia,
also the specific variants implied by our analysis play a role in the
aetiology of schizophrenia. We recognize that this is not a full
replication of the main result of this study, since no formal ISUB
analysis was performed on the replication sample. However, the
result provides strong evidence with regard to the contribution of
rare coding variants to the disease.
Previous work by Purcell et al.6 demonstrates enrichment of
primarily ultra-rare nonsense variants in schizophrenia in a set of
pre-selected genes. Our results also implicate non-synonymous
and splice site SNVs at a genome-wide level. In addition, our
analysis targets variants from a relatively rare allele frequency
spectrum, not including ultra-rare variants. As a result, most
individuals carry multiple rare SNVs, enabling us to examine the
individual cumulative burden.
We chose to study ISUB variants rather than including variants
based on allele frequency thresholds to maximize detection of the
true signal from the rare variants contributing to disease. Limiting
the alleles to singletons, for example, only diminishes the signal
by excluding variants occurring more than once in either cases or
controls. Alternatively, imposing a frequency threshold may
increase noise by including variants with an equal MAF in both
groups. Examining variants unique to either cases or controls, but
without imposing a frequency threshold, is an appealing
intermediate for studying rare variant burden. ISUB analysis is
especially advantageous when studying sample and variant sets of
a limited size, such as our sample, as it generates a more
informative signal than one obtained from setting extreme
frequency thresholds. As sample sizes increase beyond a certain
size, however, the power to assess individual burden by ISUB may
decrease. Under those circumstances, different selection criteria
of SNVs and genes are needed. We propose the approach of
selecting variants below a certain frequency threshold based on
association P values.
The observed enrichment of genes expressed in fetal brain fits
well within the existing body of evidence that schizophrenia is of
neurodevelopmental origin2,10–12. We stress, however, that
further research and a more extensive functional understanding
of pathways and gene–gene interactions is essential to corroborate
this hypothesis.
In our study, we do not observe a relationship between
common and rare susceptibility alleles. While the absence of a
significant overlap between rare variant genes and GWAS genes
(empirical P¼ 0.07) may be due to a lack of power, the absence of
a correlation between ISUB scores and common variant burden
suggests that common and rare disease risk alleles may be
independently and additively enriched in cases versus controls.
Regarding genes containing previously reported de novo
mutations in schizophrenia, we also did not observe a difference
between overlap in cases and in controls. However, the overlap
within each group was highly significant. This may suggest
that these previously reported genes are prone to (de novo)
mutational events in general, but perhaps this is not specific to
schizophrenia.
In summary, we observe an increased burden of deleterious
coding variants in schizophrenia at a genome-wide level. The
genes containing rare coding variants significantly overlap
with genes expressed in fetal brain highlighting the potential
involvement of neurodevelopment in disease aetiology11. Our
results are an important step towards a better understanding of
the genetic architecture of schizophrenia and the extensive
polygenic nature of disease susceptibility, also at the level of rare
variants.
Methods
Sample description and genotyping. We genotyped 1,042 schizophrenia cases
and 961 unaffected controls1,4,13 from a relatively homogeneous Dutch
population14 using the Illumina HumanExome BeadChip array. In-patients and
outpatients were recruited from different psychiatric hospitals and institutions
throughout the Netherlands, coordinated via academic hospitals in Amsterdam,
Groningen, Maastricht and Utrecht. Detailed medical and psychiatric histories
were collected, including the Comprehensive Assessment of Symptoms and History
(CASH), an instrument for assessing diagnosis and psychopathology. Only patients
with a DSM-IV diagnosis of schizophrenia were included as cases; controls were
volunteers, free of any psychiatric history4,5,13. The exome array includes
4250,000 putative functional exonic single-nucleotide polymorphisms (SNPs)
observed multiple times in whole-genome and exome sequence data from over
12,000 subjects15. This array was designed as an intermediate platform between
exome sequencing and common SNP arrays for studying relatively rare coding
SNPs with MAF Z0.01 %. For more details on the exome SNP array design see
(http://genome.sph.umich.edu/wiki/Exome_Chip_Design). All samples were
genotyped at UCLA Neurosciences Genomics Core with cases and controls
randomized on plates. This study was approved by the UCLA Institutional Review
Board and all subjects provided informed consent.
Quality control. We applied the following quality control to our original data set
using PLINK(v1.08p)16. We excluded samples with ambiguous sex or with imputed
sex inconsistent with our database (n¼ 20), as well as samples with missing
genotyping45% (n¼ 3). On the basis of a set of 13,597 SNPs with a MAF410%,
missing genotype rate of at most 1%, with maximum LD R2 of 0.2, we excluded
samples for too high (4meanþ 3 s.d.) or too low (omean 3 s.d.) heterozygosity
(n¼ 9), as well as samples related up to the level of distant cousins (n¼ 37).
We excluded one individual based on multidimensional scaling cluster of the two
principal components (n¼ 1) (Supplementary Fig. 2). On the basis of the resulting
set of 1,002 cases and 931 controls, we removed 307 SNPS with a missing
genotyping rate45%, as well as the SNPs located on the X and Y chromosome and
mitochondrial SNPs. Finally, we excluded flagged sites as tabulated here
ftp://share.sph.umich.edu/exomeChip/IlluminaDesigns/cautiousSites/cautiousSite.
sorted.sites
Our subsequent analysis was based on 234,353 remaining autosomal SNPs.
Variant selection and ISUB score. To quantify the burden of rare coding variants
in our sample, we computed an ISUB score using the following method. To begin,
variants occurring only in cases (‘case set-unique’ n¼ 17,035) and variants
occurring only in controls (‘control set-unique’ n¼ 13,529) were selected. This set
of variants included in ISUB analysis is likely to be a lower bound on the number of
actual rare variants in the data set, as it was shown in previous work that the
standard variant caller GenCall, developed by Illumina, has a bias towards not
being able to call singleton heterozygote variants17.
We compared the allele frequency of our set-unique SNVs with the ESP6500
database (http://evs.gs.washington.edu/EVS/ accessed on 20 October 2014). From
30,564 set-unique variants, a total of 27,544 were included in the database. The
mean MAF of the variants is 0.046% based on the population of European ancestry
(n¼ 4,300, with a median 0.035% s.d. 0.051% min 0.00%, max 1.01%). This implies
the average frequency of our variants is around 1:1,000 in the population.
To assign a numeric score to the relative deleteriousness of each variant, we
applied a previously developed CONsensus DELeteriousness (CONDEL) scoring
algorithm7. This consensus scoring metric integrates the output of five existing
prediction tools aimed at assessing the impact of non-synonymous SNVs on
protein function and holds a value between 0 and 1. These five tools included in the
consensus method are SIFT, Polyphen2, MAPP, LogR and Pfam E-value. In
addition to assigning a continuous score, the CONDEL algorithm also classifies
variants as deleterious or neutral based on a weighted average of the assigned scores.
The array also includes splice site (n¼ 12,662) and stop-altering (n¼ 7,137)
SNVs that we obtained from ftp://share.sph.umich.edu/exomeChip/
ProposedContent/codingContent/
Because most of these variants do not cause amino-acid changes, many are not
scored by the CONDEL algorithm. To include them in our analysis, we therefore
augmented the CONDEL function by assigning a maximal score and a deleterious
label all non-scored splice site and stop-altering variants. Finally, for each subject,
we computed a burden score as the sum of scores of all observed set-unique non-
synonymous SNVs (denoted NS) as well as only the set-unique non-synonymous
SNVs predicted to be deleterious (denoted DEL).
Statistical analysis. The P values are estimated empirically by permuting
phenotypes within subgroups of cases and controls 10,000 times. For each
repetition, we determined the set of unique variants and the individual scores based
on the current case-control assignments and computed the Wilcoxon test statistic.
This method both corrects for the differences in sample size in cases versus controls
and is conservative with respect to potential outliers driving the signal.
Correction for multiple testing was performed empirically using the family-wise
‘minP’ method also employed in Purcell et al.6. For each permuted version of the
data we computed the minimal empirical significance of each data set, and
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compared the empirical P value of a given test to the distribution of minimal
P values across all tests in each family. This procedure was adopted to preserve
family-wise error rates without overcorrection.
The families of tests considered in our analysis are the following: Primary
burden analysis (Table 1: One test for all, deleterious, and Benign variants—3 tests),
Gene burden analysis (Table 2: One test for each gene set—4 tests), GWAS and
de novo gene list overlap (Supplementary Table 2—2 tests).
We also present a number of exploratory/descriptive results for which we only
report uncorrected P values. These include Burden analysis comparing average
number of SNVs versus score per SNV (Supplementary Table 1), additional
observations presented in the Supplementary Material only.
Replication data set. A total of 5,585 European ancestry schizophrenia cases and
8,103 controls were used to replicate our main finding. The cases were taken from
two collections, Cardiff COGS and CLOZUK, both of which contributed to the
recent GWAS study from the Psychiatric Genomics Consortium1. Two groups of
UK controls were used in this study; UK Blood Service donors (4,455 samples) and
the 1958 British Birth Cohorts (4,615 samples)18–20. From these subjects we
obtained individual minor allele counts of deleterious rare variants identified
through ISUB analysis on our data.
DAVID analysis. We defined a set of ‘differentially hit’ genes as those genes with
deleterious variants observed in more than two cases and with an increased burden
in cases versus controls using Fisher exact P value threshold of 0.5. For controls, the
set is defined analogously. In particular, because of gene limits, our analysis
excludes those genes affected by a deleterious variant in exactly one or two cases,
versus zero controls and vice versa. We have analysed these genes separately
(Supplementary Methods).
Standard DAVID (http://david.abcc.ncifcrf.gov/ version 6.7, accessed January
2015) settings were used for functional annotation of gene sets included in our
analysis. Databases included to annotate gene list for tissue expression are
GNF_U133A_QUARTILE, PIR_TISSUE_SPECIFICITY and UP_TISSUE and
for pathways are BBID, BIOCARTA, EC_NUMBER, KEGG_PATHWAY,
PANTHER_PATHWAY, REACTOME_PATHWAY. The full results can be found
in Supplementary Table 2.
Gene list overlap. We tested for the overlap between genes contained in the
GWAS associated intervals Schizophrenia Working Group of the Psychiatric
Genomics Consortium1 (ED Supplementary Table 3). P value for the difference
in overlap between cases and controls was computed empirically by permutation
(see also Supplementary Table 2). We adopted the same analysis to test for genes
containing previously reported de novo mutations (Supplementary Tables 1 and 2
from Fromer et al.2).
Quantifying the contribution of rare variants to schizophrenia. To determine
the relative effect size of ISUB variants, we fit the following logistic regression
model on a subset of 385 controls and 708 cases included in the GWAS analysis1
Logit SCZð Þ ¼ SEXþMDS1þMDS2þMDS3þMDS4þGWASþ ISUB ð1Þ
where MDSi indicated the ith multidimensional scaling component, based on
13,597 independent common SNPS (see Quality Control).
GWAS is the polygenic risk score with a P-value cutoff of 0.05 with our samples
removed13.
ISUB is the deleterious ISUB score, corrected for sample size by multiplying the
scores of cases by jTotal Sample jj cases j ¼ 19331002 and analogously for controls, and normalized
by inverse normal transformation.
Variation explained by ISUB as well as polygenic risk scores (GWAS) are
measured by the reduction in R2 comparing the full logistic regression model
versus a reduced model with that term removed, as proposed by Nagelkerke21.
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